Stay up to date
with the latest developments at Trince Bio

Trince is included in the “Emerging technologies & companies in cell & gene therapy manufacturing” review in the Tools of tomorrow issue of Cell & Gene Therapy insights.

We are delighted to welcome Emilie Viey, PhD to the Trince team as our new Chief Commercial Officer. 

Together with Revatis, we successfully used our LumiPore transfection platform to deliver macromolecules into equine and human mesenchymal stem cells.

We are proud to announce that Clarivate has included both our scientific co-founders in their prestigious list of Highly Cited Researchers for 2022.

With 82 citations within one year after publication, our Nature Nanotechnology tpaper has received the status of Hot Paper by Web of Science.